IRIS

Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)

CASRN 111-76-2

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (31 pp, 297 K) last updated: 03/31/2010

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hematologic 1 x 10-1 Hemosiderin deposition in the liver BMDL (HED): 1.4
mg/kg-day
10 Medium/High

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (31 pp, 297 K) last updated: 03/31/2010

System RfC (mg/m3) Basis PoD Composite UF Confidence
Hematologic 1.6 Hemosiderin deposition in the liver BMCL (HEC): 16
mg/m3
10 Medium/High

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (31 pp, 297 K) last updated: 03/31/2010

WOE Characterization Framework for WOE Characterization
Not likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), EGBE is deemed "not likely to be carcinogenic to humans" at environmental concentrations at or below the RfD and RfC, based on laboratory animal evidence, mode-of-action information, and limited human study information.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (31 pp, 297 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (31 pp, 297 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.